alpha-Cubebene is a tricyclic sesquiterpene hydrocarbon found in a wide range of plant volatile profiles. In the AromaForge archive it is currently better documented as an occurrence and biosynthesis constituent than as a standalone bioactive. The public evidence supports alpha-cubebene as a recurrent sesquiterpene marker in manuka and other aromatic oils, while direct constituent-specific safety and mechanism data remain sparse.
Chemical identity and composition
PubChem identifies alpha-cubebene as C15H24. In the archive's manuka record, alpha-cubebene was reported at 4.69%, and the literature also reports it as a smaller constituent in Lepidagathis fasciculata oil at 2.8%, reinforcing its role as a sesquiterpene hydrocarbon contributor in complex volatile mixtures.
Aroma and practical use
- Use the recorded herbal, waxy, woody, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
occurrence in manuka
The AromaForge manuka record cites a GC-MS batch sheet reporting alpha-cubebene at 4.69% of the tested oil.
Measured: relative abundance
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
occurrence in other volatile oils
A Natural Product Communications paper reported alpha-cubebene at 2.8% in hydrodistilled Lepidagathis fasciculata flowering aerial-part oil.
Measured: relative abundance
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
biosynthetic context
A Phytochemistry study found that recombinant LoTPS4 produced alpha-cubebene as a minor sesquiterpene product from farnesyl diphosphate, placing alpha-cubebene within a directly characterized floral scent biosynthetic pathway.
Measured: sesquiterpene product profile from FPP
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo constituent-specific dermal limit, IFRA standard, or phototoxicity study was located in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The Good Scents Company snippet did not provide a usable constituent-specific fragrance-use limit for alpha-cubebene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
terpene synthase minor product formation
A Phytochemistry paper on Lilium 'Siberia' reported that recombinant LoTPS4 generated trans-alpha-bergamotene as a major product from FPP and alpha-cubebene as one of the minor sesquiterpene products.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No isolated human clinical studies specific to alpha-cubebene were located in the reviewed public sources.
- No strong constituent-specific pharmacology paper was located beyond biosynthesis and occurrence-focused literature.
- Constituent-specific sensitization, dermal-limit, and phototoxicity data were not located in the reviewed public sources.
- Re-verification pass (2026-07-13, 2 searches): no IFRA/Tisserand & Young/EU Annex III/peer-reviewed dermal limit, sensitization, or phototoxicity data for alpha-cubebene was located. The existing dermal_limit_pct (25) and sensitizing (true) values remain unsourced placeholders and dermal_limit_verified is correctly left false; these values were left unchanged pending a citable source, per policy of not guessing or fabricating.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.